Business
Plandaí Biotechnology to Focus on International Nutraceutical Cannabis Opportunities
Plandaí Biotechnology to Focus on International Nutraceutical Cannabis Opportunities.
About this update from Plandai Biotechnology, Inc.
[{"type":"text","content":"\nFull-Profile Non-Psychoactive Cannabis Extract To Target Pain Relief and Other Over the Counter Applications\n LONDON, UNITED KINGDOM, June 19, 2018 (GLOBE NEWSWIRE) -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) (\"Plandaí\" or \"the Company\"), producer of the highly bioavailable Phytofare® catechin complex, today discussed its focus on developing the international nutraceutical market for its full-profile, non-psychoactive cannabis extract. The international market for nutraceutical or wellness products is expected to reach $302,306 million by 2022 from $184,092 million in 2015, with an annual growth rate of 7.04% from 2016 to 2022. Recent innovations and findings of function-specific antioxidants are expected to create new opportunities in the international sector,  and the Company believes its highly bioavailable, full-profile, non-psychoactive cannabis extract will play a role in this emerging growth market. Certainly, cannabis is an emerging innovation in this sector, as shown by the rapid acceptance of cannabis for medicinal use in many countries including Argentina, Australia, Canada, Chile, Denmark, Greece, Israel and Italy. Callum Cottrell-Duffield, Chief Operating Officer of Plandaí, explained, “Our focus is on getting a full-profile, non-psychoactive cannabis extract product to market as quickly as possible so that customers can have access to a wellness product that specifically targets the pain receptors of the human endocannabinoid system.  In light of the current prescription opioid epidemic, we believe that a non-psychoactive, non-addictive pain reliever will be a welcome option for those suffering from both short-term and chronic pain.  Millions of people around the world currently treat pain symptoms with cannabis but taking a psychoactive is not ideal for many people, especially children, the elderly, and the chronic sufferers.  We have the potential to produce an highly bioavailable, full-profile, non-psychoactive cannabis product that can be delivered in a one-a-day capsule.” The human endo-cannabinoid system helps modulate a variety of functions, including pain, memory, mood, and locomotor activity. CB1 receptors are found predominantly in the brain and nervous system, as well as in peripheral organs and tissues, and are the main molecular targ...